Aphios Corporation

Drug Discovery

The discovery of anticancer drugs, anti-infectives and quality-of-life medicines from marine organisms, terrestrial plants and microorganisms from extremeophilic environments can be enhanced by utilizing SuperFluids™ CXF fractionation technologies [U.S. Patents].

Aphios is screening its unique library of 1,400+ diverse marine microorganisms, isolated from normal to extremeophilic environments in United States territorial waters, for antiviral and antimicrobial therapeutics. Our discovery portfolio includes several anti-HIV, anti-influenza and anti-smallpox “hits,” and a marine antimicrobial compound that is effective against oral microorganisms that cause plaque, caries and gingivitis, multi-drug resistant (MDR) human pathogens such as methicillin-resistant Staphylococcus aureus [MRSA] and vancomycin-resistant Enterococcus faecium [VRE], and Bacillus anthracis [anthrax].

Our research has been funded through grants and collaborations with the Department of Commerce, National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH). We have ongoing research agreements with the National Institute of Allergy and Infectious Diseases (NIAID), United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Armed Forces Institute of Pathology (AFIP).

Our business strategy is to discover, develop and license out these compounds to strategic corporate partners. We will also out-license SuperFluids™ CXF technologies to strategic corporate partners and research institutions.